United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - clarithromycin - modified-release tablet - 500mg

Israel - English - Ministry of Health

tradis gat ltd - fidaxomicin - film coated tablets - fidaxomicin 200 mg - fidaxomicin - dificlir is indicated for the treatment of clostridium difficile infections (cdi) also known as c. difficile associated diarrhoea (cdad) in adult and paediatric patients aged 6 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 50mg;  ;   - oral granules - 50 mg - active: ivacaftor 50mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate mannitol sodium laurilsulfate sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have an r117h cftr mutation (see section 4.2 dose and method of administration) or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 75mg;  ;   - oral granules - 75 mg - active: ivacaftor 75mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate mannitol sodium laurilsulfate sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have an r117h cftr mutation (see section 4.2 dose and method of administration) or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 25mg;   - oral granules - 25 mg - active: ivacaftor 25mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate mannitol sodium laurilsulfate sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have an r117h cftr mutation (see section 4.2 dose and method of administration) or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

New Zealand - English - Medsafe (Medicines Safety Authority)

leo pharma limited - azelaic acid 20% - topical cream - 20 % - active: azelaic acid 20% excipient: benzoic acid cetearyl octanoate glycerol cutina cbs polyethylene glycol 200 monostearate propylene glycol purified water - topical treatment of acne vulgaris.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluconazole -